Holen Sie sich die Stockscreener-App
12.21
2.52%
-0.315
Schlusskurs vom Vortag:
$12.52
Offen:
$12.72
24-Stunden-Volumen:
1.23M
Relative Volume:
0.81
Marktkapitalisierung:
$1.27B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-135.21M
KGV:
-8.5284
EPS:
-1.4311
Netto-Cashflow:
$-114.35M
1W Leistung:
-7.26%
1M Leistung:
-7.04%
6M Leistung:
+37.29%
1J Leistung:
+7.82%
1-Tages-Spanne:
$12.16
$12.93
1-Wochen-Bereich:
$12.16
$14.12
52-Wochen-Spanne:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.21 | 1.36B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-12 | Fortgesetzt | Stifel | Buy |
| 2026-05-15 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Form 144 Oric Pharmaceuticals For: 1 October By Investing.com - Investing.com Canada
ORIC Pharmaceuticals (ORIC) CFO Dominic Piscitelli Sells 13,400 Shares - GuruFocus
Taxes of Oric Pharmaceuticals, Inc. – HAN:4TZ - TradingView
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $181,302.00 in Stock - MarketBeat
Oric Pharma CFO sells $181k in shares By Investing.com - Investing.com South Africa
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Oric Pharma CFO sells $181k in shares - Investing.com
After a $4.36 option exercise, Oric Pharmaceuticals (ORIC) CFO sells 13,400 shares. - Stock Titan
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 - MarketBeat
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE - MarketBeat
ORIC Pharmaceuticals CFO Dominic Piscitelli Sells 600 Shares of ORIC Stock - GuruFocus
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares By Investing.com - Investing.com Australia
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Nigeria
A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC). - Stock Titan
ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high - AD HOC NEWS
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating - Investing.com
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target - TradingView
ORIC Pharmaceuticals Initiates Coverage by BTIG -- Rating Set to Buy - GuruFocus
(ORIC) Volatility Zones as Tactical Triggers - Stock Traders Daily
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth - Moomoo
Oric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotech - DirectorsTalk Interviews
Why ORIC Pharmaceuticals (ORIC) Is Back In The Spotlight - Simply Wall Street
ORIC Pharmaceuticals Inc. (US68622P1093.SG) stock price, news, quote and history - Yahoo Finance UK
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch - AlphaStreet
ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway - tradingview.com
Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView
ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing - Yahoo Finance
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,500 |
45,199 |
38,300 |
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,200 |
41,325 |
203,472 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):